VRCA
NASDAQVerrica Pharmaceuticals Inc.
News · 26 weeks35+250%
2026-03-012026-08-23
Mix1990d
- Insider11(58%)
- Other4(21%)
- SEC Filings3(16%)
- Earnings1(5%)
Latest news
25 items- INSIDERCMO Rosenberg Noah L. bought $30,610 worth of shares (6,230 units at $4.91), increasing direct ownership by 264% to 8,587 units (SEC Form 4)4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- INSIDERChief Operating Officer Zawitz David bought $29,880 worth of shares (6,000 units at $4.98), increasing direct ownership by 29% to 27,000 units (SEC Form 4)4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- INSIDERInterim CFO Kirby John J. bought $24,650 worth of shares (5,000 units at $4.93), increasing direct ownership by 26% to 23,962 units (SEC Form 4)4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- INSIDERCEO and President Rieger Jayson bought $125,750 worth of shares (25,000 units at $5.03), increasing direct ownership by 14% to 207,593 units (SEC Form 4)4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- SECSEC Form 10-Q filed by Verrica Pharmaceuticals Inc.10-Q - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECVerrica Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- PRVerrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital— Facility will support YCANTH® commercialization, global Phase 3 program for YCANTH® in common warts and general corporate operations — — Facility provides potential for no scheduled interest or principal payments until maturity in December 2030 — — Facility provided by an entity controlled by Paul B. Manning, Verrica’s Chairman and largest shareholder — WEST CHESTER, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the closing of a credit facility of up to $27.5 million wi
- PRVerrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss the Company's financial results for the second quarter ending June 30, 2026, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-225-9448 (domestic) or 1-203-518-9708 (international) and using the conference ID: VERRICA. Participants are asked to dial in
- PRVerrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in IsraelWEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced an exclusive distribution, marketing and supply agreement ("the Agreement") granting Medomie Pharma Ltd. ("Medomie") rights to seek regulatory approval for and distribute YCANTH® for the treatment of molluscum contagiosum ("molluscum") in Israel. "We are pleased to partner with Medomie to make YCANTH available in Israel so that more patients have access to treatment for molluscum," said Jayson Rieger, PhD, MBA, President and Chief E
- PRVerrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan – – Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan, including common warts – WEST CHESTER, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that the first U.S. patient was dosed in the second clinical trial (COVE-3) in its global Phase 3 program evaluating YCANTH® (VP-102) for th
- INSIDERSEC Form 4 filed by Director Nguyen Diem4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- INSIDERSEC Form 4 filed by Director Prygocki Mark A Sr4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- INSIDERSEC Form 4 filed by Director Eichenfield Lawrence4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- INSIDERSEC Form 4 filed by CMO Rosenberg Noah L.4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- INSIDERSEC Form 4 filed by CEO and President Rieger Jayson4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Zawitz David4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- INSIDERSEC Form 4 filed by Director Corcoran Gavin4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
- SECVerrica Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- PRVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceWEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference. Jefferies Global Healthcare Conference, June 2-4, 2026Event details:Date: Thursday, June 4, 2026Time: 11:05am ETLocation: New York Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Investors/Presentations & Eve
- ANALYSTH.C. Wainwright resumed coverage on Verrica Pharmaceuticals with a new price targetH.C. Wainwright resumed coverage of Verrica Pharmaceuticals with a rating of Buy and set a new price target of $12.00
- PRVerrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQWEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ, May 19, 2026Event details:Date: Tuesday, May 19, 2026Time: 1:30pm ETLocation: NASDAQ Participants may access a live webcast of the event by clicking the link here. The webcast can a
- SECSEC Form S-8 filed by Verrica Pharmaceuticals Inc.S-8 - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECSEC Form 10-Q filed by Verrica Pharmaceuticals Inc.10-Q - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- SECVerrica Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- PRVerrica Pharmaceuticals Reports First Quarter 2026 Financial Results– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed applicator units since launch – – Company announces achievement of over 50% of current targeted enrollment in the first trial in global Phase 3 common warts program and expects to initiate the second trial in the US and Japan in mid-2026 – – Company reports total revenue of $5.0 million in Q1 2026, including U.S. YCANTH net product revenue of $4.3 million in Q1 2026, up 16.2% over previous quarter and 25.4% year-over-year – – YCANTH commercial launch in Japan by partner Torii Pharmaceu
VRCA FAQ
7 questionsWhat does Verrica Pharmaceuticals Inc. do?
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for...Where does VRCA stock trade?
Verrica Pharmaceuticals Inc. (VRCA) is listed on NASDAQ.What sector and industry is VRCA in?
Verrica Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Verrica Pharmaceuticals Inc. go public?
Verrica Pharmaceuticals Inc. (VRCA) completed its IPO in 2018.What are analysts saying about VRCA?
Verrica Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1200.00 price target on 2026-05-26. Recent price targets range from $400.00 to $2000.00.What companies are similar to VRCA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare VRCA side-by-side with any of them on Quantisnow.How can I track VRCA on Quantisnow?
Quantisnow aggregates Verrica Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VRCA to receive live email and push alerts on every new disclosure.